Emily Hayes

Articles by Emily Hayes

Emily HayesPolycythemia Vera | December 11, 2023
Knowing who is at high risk in the near term could make it easier to conduct trials of anti-thrombotic therapies.
Emily HayesPolycythemia Vera | December 13, 2023
Developed by Protagonist Therapeutics, rusfertide is a novel injectable synthetic mimetic of the natural hormone hepcidin.
Emily HayesMyelofibrosis | March 4, 2024
Mass spectrometry–based proteomics were used to learn more about how MKs drive bone marrow fibrosis.
Emily HayesMyelofibrosis | March 4, 2024
Prevalence of symptoms was assessed with the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
Emily HayesAggressive B-Cell Lymphoma | December 13, 2023
Adults older than 65 and newly diagnosed with DLBCL or DLBCL/high-grade BCL with MYC and BCL2 rearrangements were surveyed.
Emily HayesChronic Lymphocytic Leukemia | March 5, 2024
There was previously a gap in evidence when it came to how the drug works after treatment with covalent BTK inhibitors.
Emily HayesMyelofibrosis | March 4, 2024
The retrospective study evaluated if pacritinib increased PLT counts in the phase III PERSIST-2 and phase II PAC203 studies.
Emily HayesAggressive B-Cell Lymphoma | September 30, 2024
Researchers examined registry data for patients with previously untreated DLBCL or high-grade BCL treated with R-CHOP.
Emily HayesMyelofibrosis | March 4, 2024
The model could be helpful in understanding fibrotic progression in JAK2V617F mutation–positive MPNs.
Emily HayesAggressive B-Cell Lymphoma | December 1, 2023
Extrachromosomal DNA was highly expressed in 18 DLBCL cell lines and may function as a powerful prognostic indicator.